DGX
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated historical holders
total: 6
Olstein Capital Management Quest Diagnostics Incorporated transactions over time
- Total transactions:
- 24
- New positions:
- 2
- Sold out:
- 2
- Added:
- 8
- Reduced:
- 12
- Held since:
- 2020 Q4
- Held for:
- 22 quarters
- Latest activity:
- 2026 Q2
Robert Olstein has been an institutional investor in Quest Diagnostics Incorporated (DGX) since at least 2013 Q2. According to 2026 Q2 report, Robert Olstein doesn't hold any shares. In our earliest available record from 2013 Q2, Olstein Capital Management held 83,000 shares of DGX. Robert Olstein later completely sold out the position and reinvested in DGX again in 2020 Q4. Since at least 2013 Q2, Olstein Capital Management has made 23 more transactions in this position.
When did Robert Olstein exit their DGX position?
Robert Olstein no longer holds Quest Diagnostics Incorporated (DGX). They sold off their entire position in 2026 Q2, closing out an investment that began in 2013 Q2.
Has Robert Olstein reinvested in DGX after selling?
Yes, Robert Olstein has shown renewed interest in Quest Diagnostics Incorporated (DGX). After completely selling their position, they reinitiated an investment in 2020 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $129.91
- Weighted AVG sell price:
- $170.07
DGX transactions history by Olstein Capital Management
24 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$195.98
|
|
-100% (-35,800)
|
-1.53%
|
|
2026 Q1
|
1.53%
|
35,800
|
$195.98
|
$7,016,000
|
-10.50% (-4,200)
|
-0.17%
|
|
2025 Q2
|
1.35%
|
40,000
|
$179.62
|
$7,185,000
|
-13.04% (-6,000)
|
-0.2%
|
|
2025 Q1
|
1.43%
|
46,000
|
$169.20
|
$7,783,000
|
-15.15% (-8,216)
|
-0.24%
|
|
2024 Q4
|
1.44%
|
54,216
|
$150.86
|
$8,179,000
|
-1.99% (-1,102)
|
-0.03%
|
|
2024 Q3
|
1.46%
|
55,318
|
$155.25
|
$8,588,000
|
-17.44% (-11,682)
|
-0.32%
|
|
2024 Q1
|
1.46%
|
67,000
|
$133.10
|
$8,918,000
|
+15.52% (+9,000)
|
+0.2%
|
|
2023 Q4
|
1.35%
|
58,000
|
$137.88
|
$7,997,000
|
-14.71% (-10,000)
|
-0.24%
|
|
2023 Q3
|
1.42%
|
68,000
|
$121.85
|
$8,286,000
|
+3.03% (+2,000)
|
+0.04%
|
|
2023 Q2
|
1.50%
|
66,000
|
$140.56
|
$9,277,000
|
+20.00% (+11,000)
|
+0.25%
|
|
2023 Q1
|
1.22%
|
$141.47
|
+19.57% (+9,000)
|
|||
|
2022 Q4
|
1.13%
|
$156.43
|
-31.75% (-21,400)
|
|||
|
2022 Q2
|
1.34%
|
$132.98
|
-10.13% (-7,600)
|
|||
|
2022 Q1
|
1.29%
|
$136.87
|
+78.57% (+33,000)
|
|||
|
2021 Q4
|
0.87%
|
$173.00
|
-30.00% (-18,000)
|
|||
|
2021 Q3
|
1.07%
|
$145.32
|
-3.23% (-2,000)
|
|||
|
2021 Q1
|
1.11%
|
$128.34
|
+55.00% (+22,000)
|
|||
|
2020 Q4
|
0.76%
|
$119.18
|
new
|
|||
|
2015 Q1
|
0.00%
|
$67.07
|
-100% (-59,000)
|
|||
|
2014 Q4
|
0.48%
|
$67.07
|
-28.05% (-23,000)
|
|||
|
2014 Q2
|
0.65%
|
$58.70
|
-18.00% (-18,000)
|
|||
|
2014 Q1
|
0.79%
|
$57.92
|
+7.53% (+7,000)
|
|||
|
2013 Q4
|
0.71%
|
$53.54
|
+12.05% (+10,000)
|
|||
|
2013 Q2
|
0.81%
|
$60.63
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.